ライフサイエンスコーパス: pruritus

1 of sweat ducts and leads to inflammation and pruritus.

2 ht be developed for treatment of cholestatic pruritus.

3 o participate and were found to have chronic pruritus.

4 arks of severe inflammation and allergy with pruritus.

5 s in either group were nausea, diarrhea, and pruritus.

6 in clinical signs and symptoms in particular pruritus.

7 rom B5-I neurons, is a key neuromodulator of pruritus.

8 centrations of bile acids (BAs) and profound pruritus.

9 n adverse events were headache, fatigue, and pruritus.

10 ted to participate; 405 of these had chronic pruritus.

11 f patients reported a deterioration in their pruritus.

12 clinical evaluation and treatment of chronic pruritus.

13 t the severity of neuraxial-morphine-induced pruritus.

14 teria, and more likely to report fatigue and pruritus.

15 useful for the management of opioid-induced pruritus.

16 tients with primary biliary cholangitis with pruritus.

17 skin is thought to contribute to cholestatic pruritus.

18 postoperative nausea and vomiting (PONV) and pruritus.

19 associated with inflammation and persistent pruritus.

20 o be effective for reducing the incidence of pruritus.

21 ly initiates the process that causes intense pruritus.

22 oach for histaminergic and non-histaminergic pruritus.

23 inate may be useful for treating established pruritus.

24 hould be considered in elderly patients with pruritus.

25 ing mouse TGR5), which exhibited spontaneous pruritus.

26 ropathy should be considered when evaluating pruritus.

27 1 patient discontinued ribavirin because of pruritus.

28 (LPA), as potential mediators of cholestatic pruritus.

29 ed infections, rash, urticaria, fatigue, and pruritus.

30 nd alleviation of night sweats, fatigue, and pruritus.

31 ach to topically induce PGD(2) for improving pruritus.

32 ften associated with swelling, erythema, and pruritus.

33 reotypy, diarrhea, insomnia, and dry skin or pruritus.

34 dverse events (AEs) were diarrhea, rash, and pruritus.

35 n ameliorating Th2-mediated inflammation and pruritus.

36 and to evaluate its efficacy for cholestatic pruritus.

37 at serotonin reuptake inhibitors can improve pruritus.

38 women with chronic liver disease and chronic pruritus.

39 o a maximum of 2,400 mg or until relief from pruritus.

40 chycardia, hypotension, lymphadenopathy, and pruritus.

41 ing (IASI-S); transepidermal water loss; and pruritus.

42 iary cholangitis, is largely ineffective for pruritus.

43 nistic research in patients with cholestatic pruritus.

44 vels in the systemic circulation and improve pruritus.

45 sensory network is thought to contribute to pruritus.

46 frequent AEs were throat irritation and oral pruritus.

47 lled, cross-over trial for PBC patients with pruritus.

48 rse events were mild injection-site pain and pruritus.

49 esented with a 2-week history of generalized pruritus.

50 ng fatigue, insomnia, irritability, and rash/pruritus.

51 on (five [7%] of 74 vs three [4%] of 75) and pruritus (0 of 74 vs two [3%] of 75).

52 Es were macular papular eruption (24 [29%]), pruritus (10 [12%]), and hypopigmentation (7 [8%]).

53 anal pain, 11 [12%]; bleeding, 14 [15%]; and pruritus, 10 [11%]).

54 ), rash (19%), nausea (14%), diarrhea (12%), pruritus (12%), and arthralgia (10%).

55 atients), diarrhoea (14 [12%] patients), and pruritus (13 [11%] patients).

56 nt adverse events were mild to moderate oral pruritus (13% for the 6 SQ-HDM group, 20% for the 12 SQ-

57 %] of 25 patients), asthenia (14 [56%]), and pruritus (14 [56%]).

58 tients with primary biliary cholangitis with pruritus, 14 days of ileal bile acid transporter inhibit

59 most frequently reported adverse events were pruritus (16%; one patient on placebo, four on seladelpa

60 nt-related AEs (most commonly fatigue [25%], pruritus [17%], diarrhea [13%], and rash [13%]), and 10%

61 pain/stinging/irritation (4.4% vs 4.6%) and pruritus (2.5% vs 1.5%).

62 groups were fatigue (29 [33%] vs 31 [37%]), pruritus (23 [26%] vs 16 [19%]), and rash (16 [18%] vs 1

63 ion (37% each); nausea (31%); fatigue (26%); pruritus (23%); and mucositis (23%).

64 79]), erythema (20 [40%] of 50 [26-55]), and pruritus (41 [82%] of 50 [69-91]) after vaccination by m

65 in the telaprevir phase were fatigue (47%), pruritus (43%), anemia (42%), nausea (37%), rash (35%),

66 l behaviour (6 [6%]), asthenia (6 [6%]), and pruritus (5 [5%]).

67 ted acute dermatitis (36% vs 69%; P < .001), pruritus (54% vs 81%; P < .001), breast pain (55% vs 74%

68 vomiting, and one with diarrhoea), then oral pruritus after 6.3% of doses (76 participants) and wheez

69 EP patients experienced less severely scored pruritus after PEBD (ALGS, 100% vs. 9% severe; FIC1, 64%

70 ting data: eczema, psoriasis, acne vulgaris, pruritus, alopecia areata, decubitus ulcer, urticaria, s

71 Patients with cholestatic disease exhibit pruritus and analgesia, but the mechanisms underlying th

72 y outcome measures included the reduction of pruritus and burning and/or pain according to a visual a

73 ough not uniformly, result in improvement of pruritus and cholestasis.

74 patient had achieved complete resolution of pruritus and clinical manifestations of the disease, as

75 holestatic, but not other forms of, systemic pruritus and closely correlates with the effectiveness o

76 l insights in signal transmission related to pruritus and discuss pruritogen candidates in cholestasi

77 Alagille syndrome (AGS) causes intractable pruritus and disfiguring xanthomas because of retained b

78 after ingestion of flatfish and yellowtail, pruritus and dyspnea occurred.

79 Intrahepatic cholestasis of pregnancy is pruritus and elevated bile acids in the second half of p

80 The diagnosis was made by maternal pruritus and elevation of total fasting bile acid (BA) (

81 ed on our hospital because of cough, sputum, pruritus and erythema.

82 Pulsed-dye laser was used for pruritus and erythema; fractional CO2 laser was used for

83 dermatitis with age that is characterized by pruritus and excoriations.

84 New insights into the pathogenesis of pruritus and fatigue have resulted in new treatment stra

85 Pruritus and health-related quality of life (HRQoL) were

86 These results suggest that pruritus and hyperalgesia in chronic cholestatic BDL rat

87 usion, PEBD is effective for treating severe pruritus and hypercholesterolemia in AGS patients withou

88 preterm babies had significantly early onset pruritus and ICP was diagnosed earlier.

89 meta-analysis, UDCA is effective in reducing pruritus and improving liver test results in patients wi

90 ciated with an increase in the perception of pruritus and in HSA in some patients.

91 he effect of gabapentin on the perception of pruritus and its behavioral manifestation, scratching, i

92 of proteinase-activated receptor 2-mediated pruritus and MyD88-mediated spongiosis.

93 1 (ECE-1) as a key regulator of ET-1-induced pruritus and neural signaling of itch.

94 pruritic syndromes, including brachioradial pruritus and notalgia paresthetica, have been associated

95 These mechanisms could contribute to pruritus and painless jaundice that occur during cholest

96 nifested clinically with tumor site pain and pruritus and pathologically with alterations in the tumo

97 s mediating the relationship between chronic pruritus and quality of life are poorly understood.

98 fic liver disease, characterized by maternal pruritus and raised serum bile acids.

99 f life of those affected through symptoms of pruritus and recurrent skin lesions.

100 The severe pruritus and relatively earlier time until death induced

101 we observed, in all patients, a decrease of pruritus and serum bile acid concentration (BAC) as well

102 It has frequently been speculated that pruritus and skin lesions develop after topical exposure

103 re, the dual effects of H(4)R antagonists on pruritus and Th2-cell-mediated inflammation point to the

104 An effect of these immunologic treatments on pruritus and the disturbed microbiome in patients with A

105 e duct ligation (BDL) as a model for hepatic pruritus and then to evaluate the contribution of inflam

106 luding vasculogenesis, fibrosis, cholestatic pruritus and tumour progression.

107 ema generally presents with urticaria and/or pruritus and will respond to conventional treatment with

108 diversion (PEBD) is effective for relief of pruritus and xanthomas in AGS patients who fail conventi

109 gle-agent activity (including improvement in pruritus) and an acceptable safety profile, making it an

110 s with early satiety, night sweats, fatigue, pruritus, and cough achieved rapid and durable improveme

111 re attributed to pembrolizumab were fatigue, pruritus, and decreased appetite, with no clear differen

112 adverse events included headache, asthenia, pruritus, and diarrhea.

113 attributed to treatment were fatigue, rash, pruritus, and diarrhea; most of the adverse events were

114 t adverse events were asthenia and headache, pruritus, and fatigue.

115 to have a lower activity level, more severe pruritus, and more advanced disease.

116 associated with nivolumab included fatigue, pruritus, and nausea.

117 cancer, fibrosis, inflammation, cholestatic pruritus, and pain.

118 AEs, particularly fever, myalgias, pruritus, and proteinuria/hematuria, occurred in 83% vs

119 ion of inhibitory interneurons that regulate pruritus, and provide evidence that the loss of inhibito

120 Diarrhea, pruritus, and rash were the most common treatment-relate

121 n adverse events included flu-like symptoms, pruritus, and rash.

122 nts were localized swelling, pain, bruising, pruritus, and transient regional lymph-node enlargement

123 and subcutaneous tissue disorders (eg, rash, pruritus, and urticaria) with insulin glargine.

124 maculopapular eruption, lichenoid reactions, pruritus, and vitiligo have been described.

125 The pruritus- and TH2-associated novel cytokine IL-31 induce

126 7-year-old girl developed barking cough and pruritus approximately two hours after eating a frozen C

127 egulate neuropathic pain, but their roles in pruritus are elusive.

128 PONV and pruritus are frequent side-effects of neuraxial morphine

129 acting antiemetics, and strategies to manage pruritus are needed.

130 r antagonists: papulopustular rash, xerosis, pruritus as well as hair, nail, and mucosal changes.

131 The description of itch (formally known as pruritus) as an "unpleasant sensation that elicits the d

132 eading to chronic inflammatory responses and pruritus associated with contact dermatitis.

133 Upon reoccurrence of pruritus, ATX activity returned to pretreatment values.

134 Delineation of a progesterone sulfate-TGR5 pruritus axis identifies a therapeutic target for itch m

135 ession and anxiety, fatigue and sleep, pain, pruritus, body image distress, sexual function, work dis

136 These patients usually have fatigue and pruritus, both of which occur independently of disease s

137 wer than expected for nausea or vomiting and pruritus but comparable with existing data for lower ext

138 ve examined the neural networks activated by pruritus but not its behavioral response, scratching.

139 neurons and was important for inducing itch (pruritus), but was not necessary for eliciting mechanica

140 A proportion of patients report increased pruritus, but other short-term markers of quality of lif

141 Treatment of severe, refractory pruritus by the molecular adsorbents recirculation syste

142 roversion [P = .03], neuroticism [P = .01]), pruritus characteristics (severity [P < .001], duration

143 1 patients in the obeticholic acid developed pruritus compared with nine (6%) of 142 in the placebo g

144 K2330672 administration for 14 days improves pruritus compared with placebo.

145 Within a week after the surgery her pruritus completely resolved.

146 ow-up, 1 patient had persistent but improved pruritus controlled with oral antihistamines and 23 rema

147 ir flank skin in response to virally induced pruritus, die rapidly with no identifiable symptoms of c

148 to treatment was defined as normalization of pruritus, disappearance of jaundice, and alanine aminotr

149 e an effective, well-tolerated treatment for pruritus due to chronic liver disease.

150 Twenty one subjects with chronic pruritus due to liver disease (including primary biliary

151 31-neuron axis has been implicated in severe pruritus during atopic skin inflammation, IL-31's neurop

152 complaints including cutaneous flushing and pruritus, dysautonomia, functional gastrointestinal symp

153 50; these additional five skin problems were pruritus, eczema, impetigo, scabies, and molluscum conta

154 Adverse events, mainly rash, pruritus, erythema, mouth and tongue disorders, and tast

155 se events (AEs), predominantly manifested by pruritus, erythema, wheal, or eczema.

156 in the genital area) and generalized truncal pruritus (especially in patients with diabetes mellitus)

157 grade 3 and 4 events were pain in the vulva, pruritus, fatigue, and headache.

158 commonly reported adverse effects were rash, pruritus, fatigue, and insomnia.

159 eported in at least 10% of the patients were pruritus, fatigue, and nausea.

160 -week group; 12 [20%] in the 16-week group), pruritus (five [8%] in the 12-week group; 14 [23%] in th

161 PEBD for 14 years experienced an increase in pruritus from grade 1 to grade 4 within 2 months of elec

162 All 9 patients had severe, mutilating pruritus (grade 4) prior to diversion.

163 tch that would subsequently develop ICP from pruritus gravidarum (group 2: ICP n = 41, pruritus gravi

164 om pruritus gravidarum (group 2: ICP n = 41, pruritus gravidarum n = 14).

165 onset of ICP and distinguish it from benign pruritus gravidarum, enabling targeted obstetric care to

166 lestasis of pregnancy (ICP) or due to benign pruritus gravidarum.

167 ding weight loss, fatigue, night sweats, and pruritus, had rapid improvement.

168 y paresthesia, arthralgia, myalgia, malaise, pruritus, headache, dizziness, metallic taste, visual di

169 Pruritus, headache, nausea, rash, and dizziness were hig

170 ncy (ICP) affects 1/140 UK pregnancies; with pruritus, hepatic impairment and elevated serum bile aci

171 e) adverse events (including erythema, rash, pruritus, hyperpigmentation, pain, hypopigmentation, and

172 mine-challenged subjects developed immediate pruritus (i.e. within the first 5 min).

173 hould be included in the initial therapy for pruritus in all elderly patients.

174 eutic approaches for patients suffering from pruritus in cholestasis.

175 There was a trend toward decreased pruritus in FIC1 after IE and GBC.

176 y nerves by directly regulating ET-1-induced pruritus in humans and mice.

177 1/2 pathway as a therapeutic target to treat pruritus in humans.

178 a bullous pemphigoid animal model featuring pruritus in immunocompetent, mature, and largely unmanip

179 ely reduced mast cell numbers and alleviated pruritus in JAK2V617F transgenic mice.

180 thelin 1 (ET-1) evokes histamine-independent pruritus in mammals through activation of its cognate G

181 host range alphaherpesvirus, causes violent pruritus in many different animals, but the mechanism is

182 BAs induce pruritus in mice by co-activation of TGR5 and TRPA1.

183 A1) is involved in BA-evoked, TGR5-dependent pruritus in mice.

184 Furthermore, the presence of pruritus in MPDs was statistically correlated with a gre

185 erleukin-31 (IL-31) is its ability to induce pruritus in pathologic conditions, such as atopic dermat

186 er inhibitor, a novel class of drug to treat pruritus in PBC.

187 Treatment of pruritus in primary biliary cholangitis is challenging a

188 icant and novel advance for the treatment of pruritus in primary biliary cholangitis.

189 n atopic dermatitis (AD) is the induction of pruritus in the skin.

190 tion, TLR3 knockdown in DRGs also attenuated pruritus in WT mice.

191 haracteristics of patients and their chronic pruritus) in multivariate analysis using ItchyQoL scores

192 mination in any case of persistent localized pruritus, in the absence of primary dermatologic causes.

193 ue, nausea, diarrhea, emesis, headache, rash/pruritus, increased AST/ALT, and anorexia.

194 erized by intermittent jaundice, intractable pruritus, increased serum bile acid (BA) levels, and nor

195 Nausea, pruritus, insomnia, diarrhea, and asthenia occurred in s

196 actor 19 levels, but only marginally altered pruritus intensity and ATX activity.

197 en candidate studied so far, correlates with pruritus intensity and responds to therapeutic intervent

198 patic cholestasis (PFIC) is characterized by pruritus, intrahepatic cholestasis, low serum gamma-glut

199 Chronic debilitating pruritus is a cardinal feature of atopic dermatitis (AD)

200 Pruritus is a cardinal symptom of atopic dermatitis, and

201 Persistent pruritus is a common disabling dermatologic symptom asso

202 Pruritus is a common problem among elderly people and, w

203 Chronic pruritus is a common problem with a deleterious effect o

204 Pruritus is a common symptom in patients with cholestati

205 Pruritus is a common symptom in patients with Philadelph

206 Persistent localized pruritus is a rare manifestation of central nervous syst

207 Pruritus is a seriously disabling symptom accompanying m

208 Pruritus is defined as the second order of nociception,

209 Pruritus is frequently the most debilitating symptom of

210 Neuropathic pruritus is infrequently considered but may cause locali

211 In many diseases, pruritus is not effectively treated with antihistamines,

212 V), and the pathophysiology of PV-associated pruritus is unclear.

213 The pathophysiology of MPD-associated pruritus is unclear.

214 de of special circumstances (eg, intractable pruritus), is undermined by the absence of evidence for

215 Itch, also known as pruritus, is a common, intractable symptom of several sk

216 Chronic itch, or pruritus, is associated with a wide range of skin abnorm

217 Itching, or pruritus, is defined as an unpleasant cutaneous sensatio

218 emotional and psychosocial impact of chronic pruritus, it is important to accurately assess and measu

219 NaV1.7-dependent model of histamine-induced pruritus (itch) and additionally in a capsaicin-induced

220 nts with primary biliary cholangitis develop pruritus (itch) during the course of their disease.

221 In humans, pruritus (itch) is a common but poorly understood sympto

222 Pruritus (itch) is a symptom commonly experienced by pat

223 search for new methods to alleviate clinical pruritus (itch).

224 jor signs and symptoms of PBC, which include pruritus, lethargy, the sicca syndrome, and osteoporosis

225 Secondary readouts were changes in pruritus, levels of histamine IL-6, IL-8 and TNF-alpha c

226 he effects of ursodeoxycholic acid (UDCA) on pruritus, liver test results, and outcomes of babies bor

227 opathic pain, fibrotic diseases, cholestatic pruritus, lymphocyte homing, and thrombotic diseases by

228 fter several months of localized intractable pruritus, magnetic resonance imaging of the cervical spi

229 wever, there was no significant reduction in pruritus (MD, 2.1 [95% CI, 0.5 to 3.7] [P = .16]) and in

230 9 to 51.2] [P = .009]) and the VAS score for pruritus (MD, 4.6 [95% CI, 1.5 to 7.7] [P = .005]) and b

231 mptoms including rash, arthralgia, headache, pruritus, myalgia, and fever.

232 erapy (less hematologic toxicity; more rash, pruritus, neuropathy, and alopecia).

233 intensity and ATX activity in patients with pruritus not responding to bile salt sequestrants.

234 dverse events related to Opra Kappa included pruritus, observed in a subset of individuals.

235 Pruritus occurred more frequently with the active regime

236 Pruritus occurred significantly more frequently in the l

237 Pruritus occurs frequently in patients with polycythemia

238 UDCA was associated with total resolution of pruritus (odds ratio [OR], 0.23; 95% confidence interval

239 resented with signs of localized intractable pruritus of 6 months' duration on the left side of the n

240 increased serum ATX levels are specific for pruritus of cholestasis, but not pruritus of uremia, Hod

241 ly represents a novel therapeutic target for pruritus of cholestasis.

242 he need to differentiate whether gestational pruritus of the skin is an early symptom of intrahepatic

243 dered in children with intractable localized pruritus of unknown etiology of the head and neck or upp

244 pecific for pruritus of cholestasis, but not pruritus of uremia, Hodgkin's disease, or atopic dermati

245 stration, she developed a heat sensation and pruritus on her neck, with flushing, abdominal pains, br

246 ignificantly influence the impact of chronic pruritus on quality of life demonstrates the complex nat

247 Factors that mediated the impact of chronic pruritus on quality of life were demographic characteris

248 e effects of UDCA with placebo, UDCA reduced pruritus (OR, 0.21; 95% CI, 0.07-0.62; P < .01), normali

249 no symptoms of early satiety, night sweats, pruritus, or erythromelalgia.

250 the presence of discharge, dysuria, genital pruritus, or genital irritation or odor.

251 osing cholangitis include fatigue, jaundice, pruritus, or steatorrhoea.

252 a "4P" Scar Scale (UNC4P), which rates pain, pruritus, paresthesias, and pliability.

253 5% of patients in either group were fatigue, pruritus, rash, and diarrhea.

254 igue, nausea, headache, dizziness, insomnia, pruritus, rash, and vomiting.

255 rviews and by a visual analog score (VAS) of pruritus recorded every hour while patients were awake.

256 tic approach for patients with chronic liver pruritus refractory to conventional treatments.

257 ssion (TTP), duration of response (DOR), and pruritus relief ( > or = 3-point improvement on a 10-poi

258 sive disease (TTP), response duration (DOR), pruritus relief, and safety were determined.

259 Overall, 32% of patients had pruritus relief.

260 Fourteen of 31 evaluable patients had pruritus relief.

261 This Review highlights selected frontiers in pruritus research and focuses on recently attained insig

262 late in life and is characterized by intense pruritus, resulting in a phenotype resembling acquired i

263 the investigator's global assessment score, pruritus, safety assessments, serum biomarker levels, an

264 ulgaris, bacterial skin diseases, urticaria, pruritus, scabies, cellulitis, and alopecia areata were

265 severe baseline symptom from the following: pruritus score of 9 or more, eight or more flushes per w

266 At 1 year post-PEBD, the average pruritus score was 1.1; 8 patients had only mild scratch

267 hing paralleled changes in the visual analog pruritus score.

268 estigator's global assessment (P<0.001); and pruritus scores decreased (indicating a reduction in itc

269 The key outcomes include improvement in pruritus scores evaluated on a numerical rating scale an

270 The secondary endpoints were changes in pruritus scores measured using the 0 to 10 numerical rat

271 n disease caused by a combination of intense pruritus, scratching, and epicutaneous (e.c.) sensitizat

272 nts (68%), causing tenderness or discomfort, pruritus, sensitivity to touch, and/or discomfort with b

273 vents, and demonstrated efficacy in reducing pruritus severity.

274 JNJ 7777120 also significantly inhibited the pruritus shown in the model.

275 Clinical symptoms were heterogeneous: pruritus sine materia (no primary skin lesions), eczemat

276 and family quality of life caused by intense pruritus, sleep disruption, dietary and nutritional conc

277 Finally, in a murine model of pruritus, the scratching behavior induced by compound 48

278 t frequent reported adverse events were oral pruritus, throat irritation, and nasopharyngitis.

279 Other symptoms included plugging, pruritus, tinnitus, pain, and bleeding.

280 ce, with clinical symptoms ranging from oral pruritus to fatal anaphylactic reaction.

281 Little evidence supports pruritus treatment, limiting therapeutic possibilities a

282 ognized are postherpetic itch, brachioradial pruritus, trigeminal trophic syndrome, and ischaemic str

283 -limiting toxicity, one patient) and grade 3 pruritus (two patients) were observed at 27 mg and 60 mg

284 increased the risk of arterial hypotension, pruritus, urinary retention, and motor blockade.

285 Participants quantified their pruritus using a 0-10 visual analog scale, and pruritus

286 igns (objective SCORAD), symptoms (POEM, VAS pruritus, VAS sleeping problems) and previous treatment

287 the placebo group were arthralgia, diarrhea, pruritus, vomiting, and chest pain.

288 Median duration of reduction in pruritus was 6 months.

289 The perception of pruritus was assessed by interviews and by a visual anal

290 uritus using a 0-10 visual analog scale, and pruritus was assessed for distribution, timing, degree o

291 Pruritus was more common with obeticholic acid than with

292 A clinically meaningful improvement in pruritus was observed in 28 (43%) of 65 patients, includ

293 Pruritus was the principal adverse event; incidence valu

294 Alopecia, injection site erythema, and pruritus were 13%, 27%, and 10%, respectively.

295 Follicular hyperkeratotic papules and marked pruritus were also prominent clinical findings.

296 The incidence and severity of pruritus were lowest among patients who received 10 mg/d

297 A total of 76 adults with chronic pruritus were recruited.

298 ient injection-site reactions (eg, erythema, pruritus) were the most frequent IMA901-related side-eff

299 s underlying skin-derived itch (pruritogenic pruritus), which may affect future antipruritic strategi

300 rrent study, we found frequent occurrence of pruritus with aged JAK2V617F transgenic mice and further